Pramlintide

Overview

Pramlintide is a synthetic, stable analogue of amylin — a hormone the pancreas co-secretes with insulin after a meal. Native human amylin tends to aggregate, making it unusable as a medicine; in pramlintide, three positions (25, 28, 29) are replaced by proline, which makes it soluble and stable.

This makes pramlintide the clinically travelled counterpart of cagrilintide, which sits in the same amylin axis. Where cagrilintide is a long-acting analogue in research, pramlintide is an approved, short-acting agent given at mealtimes, alongside insulin.

Pramlintide is the compound behind the approved medicine Symlin. That regulatory status is a fact about the respective authority. At Peptalis, pramlintide is available strictly for research use only — in-vitro, not for human or animal use.

Mechanism of action

Pramlintide mimics amylin and acts on the amylin/calcitonin receptors: it slows gastric emptying, suppresses post-meal glucagon and promotes satiety.

Amylin route

• Amylin is co-secreted with insulin and acts complementarily: it slows gastric emptying, suppresses post-meal glucagon and reduces appetite via the central nervous system.
• Pramlintide mimics this, complementing insulin's action at mealtimes — the same axis as cagrilintide.

Stability via proline substitutions

• Human amylin aggregates (amyloid); replacing residues 25, 28 and 29 with proline prevents this and makes pramlintide usable as an agent.
• It is short-acting and given at each meal, separately from insulin.

Research findings

• Mechanism/review: amylin physiology, pharmacology and clinical use of pramlintide (Ryan 2009)
• Human (RCT, T1D): pramlintide plus insulin improved long-term glucose and weight control, n=651, 52 weeks (Ratner 2004)
• Human (RCT, T2D): pramlintide plus insulin improved glucose and weight, n=656, 52 weeks (Hollander 2003)
• Human (RCT, T1D): long-term efficacy with open-label extension, n=480 (Whitehouse 2002)

Mechanism

• Pramlintide mimics amylin and acts on the amylin/calcitonin receptors; its physiology and pharmacology are well described (Ryan 2009).

Human studies

• In a 1-year RCT in 651 people with type 1 diabetes, pramlintide, added to insulin, improved long-term glucose control (HbA1c) and weight (Ratner 2004).
• In a 1-year RCT in 656 people with type 2 diabetes, pramlintide added to insulin likewise improved glucose and weight control (Hollander 2003).
• A randomized study with open-label extension in 480 people with type 1 diabetes confirmed the long-term effects (Whitehouse 2002).

Research context

This profile describes what has been done and found in research. Regulatory and clinical facts are facts about the respective trials and authorities, not claims about a Peptalis product; the compound is for in-vitro laboratory research only (RUO).

Open questions

• Pramlintide is short-acting and requires a separate injection at each meal; that is a practical limitation.
• The observations reported in studies include nausea and (in combination with insulin) an increased risk of low blood sugar — recorded as facts about the studies, not as a recommendation.
• Direct comparison with long-acting amylin analogues (such as cagrilintide) is limited to indirect data.

Research outlook

Pramlintide is the well-characterized, clinically validated reference point for the amylin axis.

Together with cagrilintide it makes the amylin route within the metabolic domain internally comparable: short-acting/approved alongside long-acting/in-research.

Scientific interest

The approved, clinically validated anchor of the amylin axis — a comparison neighbour of cagrilintide.

A complementary satiety mechanism alongside the incretins (GLP-1/GIP).

A large human RCT dossier in type 1 and type 2 diabetes.

Specifications

References

1. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes · Whitehouse F, et al. · Diabetes Care · 2002
2. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial · Hollander PA, et al. · Diabetes Care · 2003
3. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial · Ratner RE, et al. · Diabet Med · 2004
4. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes · Ryan G, et al. · Drug Des Devel Ther · 2009

Availability

Not in catalogue · Profile complete · verification and sourcing not yet finished